From these studies, it is clear that NfL holds promise as a disease-activity biomarker for ALD which could be used to acutely monitor the response to disease-modifying treatment, however, other neurological disorders could bias measurements and therefore this would need to be incorporated into the exclusion criteria for ALD clinical trials. Here, NEFL is linked to adrenoleukodystrophy.